

70350

(ii) $\left[\begin{array}{c} \text{(CH}_2\text{)}_2\text{-N} \\ | \\ \text{Y} \end{array} \right]$ - and forms a six membered ring

with B, said ring containing one nitrogen;

Y is

(a) C_{1-6} alkyl, or H;

(b) C(O)-C_{1-6} alkyl;

(c) $\left[\begin{array}{c} \text{CH}_2\text{CH-CH}_2\text{-Z} \\ | \\ \text{OH} \end{array} \right]$, wherein Z is C_{1-6} alkyl or O-C_{1-6} alkyl;

(d) aryl; or

(e) heterocycle;

B is a single bond, OH or halo;

C is -OH, $-\text{CH}_2-$ or forms a 5-membered lactone or lactam ring with D; and

D is:

(i) -OH, $-\text{CH}_2\text{-halo}$, $-\text{CH(O)-}$, $-\text{COOH}$, $-\text{C(O)-O-C}_{1-6}$ alkyl, $-(\text{CH}_2)_n-$, $-\text{CHOH-}$, wherein n is an integer and is 1, 2, or 3; or

(ii) forms a 5-membered lactone or lactam ring with C;

E is -H or $-\text{CH}_3$; and

F is -OH,


or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier, said

composition useful in the treatment of neoplastic diseases,

with the proviso that the formula excludes nescapine of the structure

T0360

C2
copy



and a pharmaceutically acceptable carrier therefor.